Evolving medical therapies for crohn’s disease
- 39 Downloads
Medical therapy for Crohn’s disease has changed dramatically over the past few years. Physicians have become increasingly willing to use traditional immunosuppressive agents such as azathioprine/6-mercaptopurine (6-MP) and methotrexate as well as new biologic therapies such as infliximab. Azathioprine, 6-MP, and methotrexate have demonstrated efficacy in induction and maintenance of remission in Crohn’s disease. 6-MP has also demonstrated efficacy in the pediatric population and possibly as first-line therapy. As use of the purine metabolites grows, therapeutic drug monitoring for efficacy and toxicity will become an emerging area of interest. With respect to the biologic therapies, infliximab is increasingly used to treat patients with difficult disease; however, knowledge is still evolving regarding optimal dosing schedules and the significance of immune reactions to the compound. A humanized anti-tumor necrosis factor antibody, CDP571, may be less immunogenic. Interleukin-10 did not consistently demonstrate benefit in Crohn’s disease. Similarly, antisense to intracellular adhesion molecule 1 (ISIS 2302) was not efficacious when administered either subcutaneously or intravenously. Finally, growth hormone has shown promising results in a small trial.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705–713. Study of various types of therapeutic drug monitoring and pharmacogenetic assessment of response to and toxicity from 6-MP.PubMedCrossRefGoogle Scholar
- 5.Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease: North American Crohn’s Study Group Investigators. N Engl J Med 2000, 342:1627–1632. This report demonstrates the benefit of methotrexate for maintenance of remission.PubMedCrossRefGoogle Scholar
- 7.Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease: Crohn’s Disease cA2 Study Group. N Engl J Med 1997, 337:1029–1035. Landmark paper on the use of anti-TNF therapy in Crohn’s disease.PubMedCrossRefGoogle Scholar
- 10.Remicade (infliximab): prescribing information. In Physician’s Desk Reference, edn 55. Montvale, NJ; Medical Economics:1085–1088.Google Scholar
- 14.Feagan BG, Baker JP, Feagan BG, Sandborn WJ, Baker JP, et al.: A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohns disease [abstract]. Gastroenterology 2000, 118(suppl 2):A655.CrossRefGoogle Scholar
- 18.Fedorak RN, Nielson DH, Williams NC, et al.: Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn’s disease.Gastroenterology 2001, 120(suppl 1):A681.Google Scholar
- 20.Yacyshyn BR, Chey Wy, Goff J, et al.: Double-blinded, randomized, placebo-controlled trial of the remission inducing and steroid sparing properties of two schedules of ISIS 2302 (ICAM-1 Antisense) in active, steroid-dependent Crohn’s disease. Gastroenterology2000, 118(suppl):A570.Google Scholar